Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study
Patients with Down syndrome have increased incidence of inflammatory conditions, including hidradenitis suppurativa, which may require biologic medications for optimal disease management. This retrospective cohort study evaluated 27 patients with Down syndrome and comorbid hidradenitis suppurativa and demonstrated that biologics are well tolerated and effective in this cohort.
Authors
- Christopher J. Sayed (ORCID: https://orcid.org/0000-0003-3201-4637)
- John W. Frew (ORCID: https://orcid.org/0000-0001-5042-3632)
- Alexandra Charrow (ORCID: https://orcid.org/0000-0002-3784-7091)
- Linnea Westerkam (ORCID: https://orcid.org/0000-0002-9815-9399)
- Karla Santiago-Soltero
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Ingham Institute (AU)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1093/ced/llaf090
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00